普伐他汀对急性冠状动脉综合征患者血清TNF-α和IL-6水平的影响  

Effect of pravastatin on levels of TNF-α and interleukin-6 in patients with acute coronary syndrome

作　　者：杨梅[1] 阴东亮[1] 邢林[1] 

机构地区：[1]济南市第三人民医院急诊科,山东省济南250101

出　　处：《中国基层医药》2008年第6期942-944,共3页Chinese Journal of Primary Medicine and Pharmacy

摘　　要：目的探讨普伐他汀对急性冠状动脉综合征（ACS）患者血清肿瘤坏死因子α（TNF-α）及白细胞介素6（IL-6）水平变化的影响。方法将ACS患者50例随机分为普伐他汀组25例和常规治疗组25例，分别于治疗前及治疗4周后行血清TNF-α及IL-6检测，均采用放射免疫分析方法。另选同期健康体检的20例作为对照组。结果ACS组治疗前血清IL-6、TNF-α水平均明显高于对照组（均P〈0．01）。普伐他汀组治疗后血清IL-6、TNF-α水平均明显低于治疗前，但仍高于对照组（均P〈0．05）。常规治疗组患者治疗后血清IL-6、TNF-α降低不明显（P〉0．05）。结论IL-6、TNF-α水平升高与ACS发病密切相关，普伐他汀可降低ACS患者血IL-6、TNF-α水平．具有减轻病变部位炎性反应和保护内皮细胞的作用。Objective To investigate the effect of pravastatin on serum levels of interleukin-6 （IL-6） and tumor necrosis factor-α（TNF-α） in patients with acute coronary syndromes（ACS）. Methods 50 patients with ACS were randomly divided into pravastatin group（ n = 25） and routine therapy group（ n = 25 ）. Serum TNF-α and IL-6 levels were measured before and four weeks after the two treatment options respectively. Results The level of TNF-α and IL-6 were higher than routine therapy group before therapy（P 〈 0.01 ）. The level of TNF-α and IL-6 were decreased significantly after pravastatin therapy, and higher than controls（ P 〈 0.05）. The levels of TNF-α and IL-6 changed only slightly after the routine therapy（ P 〉 0.05 ）. Conclusion The level of TNF-α and IL-6 becoming higher in ACS patients may be related to the pathogenesis of ACS. Pravastatin can reduce serum level of TNF-α and IL-6 contributing to treatment of ACS.

关 键 词：普伐他汀 白细胞介素6 肿瘤坏死因子 冠状动脉疾病 

分 类 号：R541[医药卫生—心血管疾病]